---
id: healthcare-associated-infections_118
category: clinical_syndromes
tags: [HAI, CLABSI, CAUTI, VAP, SSI, nosocomial-infections]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Healthcare-Associated Infections (HAI)

**Q:** What are the major types of healthcare-associated infections (CLABSI, CAUTI, VAP, SSI), their diagnostic criteria, common pathogens, and management?

**A:**

## OVERVIEW

**Healthcare-Associated Infection (HAI):** Infection acquired during healthcare delivery (≥48 hours after admission OR ≤10 days after discharge)

**Major HAI Categories:**
1. **CLABSI** (Central Line-Associated Bloodstream Infection)
2. **CAUTI** (Catheter-Associated Urinary Tract Infection)
3. **VAP** (Ventilator-Associated Pneumonia)
4. **SSI** (Surgical Site Infection)
5. **C. difficile Infection** (CDI)

**Key Point:** **Most HAIs are preventable** through evidence-based interventions

---

## 1. CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION (CLABSI)

### **Definition:**

**Laboratory-confirmed bloodstream infection (LCBI)** where:
- Central line in place **>2 days** on date of event (or removed day before)
- No other identified source of infection

---

### **Common Pathogens:**

| **Pathogen** | **Frequency** | **Risk Factors** |
|--------------|---------------|------------------|
| **Coagulase-negative Staphylococci (CoNS)** | 30-40% | Most common contaminant (also true pathogen) |
| **Staphylococcus aureus** (MRSA, MSSA) | 15-20% | High virulence, complicated bacteremia |
| **Enterococcus** (VRE, VSE) | 10-15% | GI translocation, immunocompromised |
| **Candida species** | 10-15% | Prolonged lines, TPN, broad-spectrum antibiotics |
| **Gram-negative bacilli** (E. coli, Klebsiella, Pseudomonas) | 15-20% | Critically ill, immunocompromised |

**Key Point:** **CoNS = most common** (but often contaminant - need ≥2 positive cultures)

---

### **Diagnosis:**

**Differential Time to Positivity (DTP):**
- **Simultaneous blood cultures** (central line + peripheral)
- **DTP ≥2 hours earlier from CVC** = suggests CLABSI

**Culture Requirements:**
- **≥1 positive blood culture** (recognized pathogen) OR
- **≥2 positive cultures** (common skin contaminant like CoNS)

---

### **Management:**

**Step 1: Source Control**
- **Remove line if:**
  - **Severe sepsis/septic shock**
  - **S. aureus, Candida, or MDR Gram-negative** bacteremia
  - **Tunnel/port infection, suppurative thrombophlebitis**
  - **Persistent bacteremia >72 hours** on appropriate antibiotics

**Step 2: Empiric Antibiotics** (adjust based on cultures)

| **Clinical Scenario** | **Empiric Regimen** |
|-----------------------|---------------------|
| **Hemodynamically stable, no MRSA risk** | **Cefepime** 2g IV q8h OR **piperacillin-tazobactam** 4.5g IV q6h |
| **MRSA risk factors** (known colonization, ICU) | **Add vancomycin** 15-20 mg/kg IV q8-12h (target trough 15-20 μg/mL) |
| **High MDRO risk** (neutropenia, recent MDRO) | **Meropenem** 1g IV q8h + **vancomycin** |
| **Candida** (TPN, prolonged line, yeast on Gram stain) | **Echinocandin** (micafungin 100 mg IV daily OR caspofungin 70 mg IV x 1 → 50 mg daily) |

**Step 3: Antibiotic Duration**

| **Pathogen** | **Line Removal** | **Line Retained** |
|--------------|------------------|-------------------|
| **CoNS** | **5-7 days** | **10-14 days** + antibiotic lock therapy |
| **S. aureus** | **14 days** (uncomplicated) OR **4-6 weeks** (complicated) | **NOT recommended** (remove line) |
| **Enterococcus** | **7-14 days** | **10-14 days** + antibiotic lock |
| **Gram-negative** | **7-14 days** | **10-14 days** + antibiotic lock |
| **Candida** | **14 days after first negative culture + line removal** | **NOT recommended** (remove line) |

**Key Point:** **S. aureus or Candida = REMOVE line** (high risk of complications)

---

## 2. CATHETER-ASSOCIATED URINARY TRACT INFECTION (CAUTI)

### **Definition:**

**Symptomatic UTI** with:
- Urinary catheter in place **>2 days** on date of event (or removed day before)
- **≥1 symptom:** Fever (>38°C), suprapubic tenderness, CVA tenderness, urinary urgency/frequency/dysuria (if catheter removed)
- **Urine culture ≥10⁵ CFU/mL** (≤2 species)

**Key Point:** **Asymptomatic bacteriuria is NOT CAUTI** (do not treat)

---

### **Common Pathogens:**

- **E. coli** (50%)
- **Enterococcus** (15%)
- **Pseudomonas aeruginosa** (10%)
- **Klebsiella pneumoniae** (10%)
- **Candida species** (especially if prolonged catheterization, diabetes, antibiotics)

---

### **Diagnosis:**

**Criteria for CAUTI:**
1. **Catheter present >2 days**
2. **Symptoms** (fever, suprapubic tenderness, CVA tenderness)
3. **Urine culture ≥10⁵ CFU/mL**

**Avoid:**
- Do NOT treat **asymptomatic bacteriuria** (common in catheterized patients)
- Do NOT culture urine without symptoms

---

### **Management:**

**Step 1: Remove/Replace Catheter** (if still needed)

**Step 2: Empiric Antibiotics**

| **Clinical Scenario** | **Empiric Regimen** |
|-----------------------|---------------------|
| **Uncomplicated CAUTI** (hemodynamically stable) | **Ceftriaxone** 1-2g IV daily OR **ciprofloxacin** 400 mg IV q12h |
| **Sepsis/shock, high MDRO risk** | **Meropenem** 1g IV q8h OR **piperacillin-tazobactam** 4.5g IV q6h |
| **Known VRE colonization** | **Add linezolid** 600 mg IV q12h OR **daptomycin** 6 mg/kg IV daily |
| **Candiduria with symptoms** | **Fluconazole** 400 mg PO/IV daily x 14 days (if susceptible) |

**Step 3: Duration**
- **7 days** (if prompt response)
- **10-14 days** (if delayed response or complicated course)

**Key Point:** **Do NOT treat asymptomatic bacteriuria/candiduria** (except pregnancy, urologic surgery)

---

## 3. VENTILATOR-ASSOCIATED PNEUMONIA (VAP)

### **Definition:**

**Pneumonia** developing **>48 hours after intubation** with:
- **New or progressive infiltrate** on CXR
- **≥2 clinical signs:** Fever (>38°C), leukocytosis/leukopenia, purulent secretions
- **Microbiologic confirmation** (preferred but not required for diagnosis)

---

### **Common Pathogens:**

**Early-Onset VAP (<5 days):**
- **S. pneumoniae, H. influenzae, MSSA**

**Late-Onset VAP (≥5 days) or MDRO Risk:**
- **Pseudomonas aeruginosa** (20-30%)
- **MRSA** (20-30%)
- **Acinetobacter baumannii** (multidrug-resistant)
- **Klebsiella pneumoniae** (ESBL, CRE)
- **Stenotrophomonas maltophilia**

**Key Point:** **Late-onset VAP (≥5 days) = high MDRO risk** (Pseudomonas, MRSA, Acinetobacter)

---

### **Diagnosis:**

**Preferred Diagnostic Methods:**
- **Endotracheal aspirate** (quantitative culture)
- **BAL (bronchoalveolar lavage)** (≥10⁴ CFU/mL) - more specific
- **Protected specimen brush** (≥10³ CFU/mL)

**Clinical Pulmonary Infection Score (CPIS):**
- Used to guide antibiotic discontinuation (score <6 at 72 hours → consider stopping antibiotics)

---

### **Management:**

**Step 1: Empiric Broad-Spectrum Antibiotics** (within 1 hour if septic shock)

**MRSA Coverage:**
- **Vancomycin** 15-20 mg/kg IV q8-12h (target trough 15-20 μg/mL) OR
- **Linezolid** 600 mg IV q12h

**PLUS Pseudomonas/Gram-Negative Coverage:**
- **Cefepime** 2g IV q8h OR **piperacillin-tazobactam** 4.5g IV q6h OR **meropenem** 1g IV q8h

**PLUS Second Pseudomonas Agent (if Septic Shock or High MDRO Risk):**
- **Ciprofloxacin** 400 mg IV q8h OR **amikacin** 15-20 mg/kg IV daily

**Step 2: De-Escalate Based on Cultures** (48-72 hours)

**Step 3: Duration**
- **7 days** (if good clinical response)
- **8-15 days** (if non-fermenting Gram-negatives like Pseudomonas, Acinetobacter)

**Key Point:** **VAP = double Gram-negative coverage + MRSA coverage** (if late-onset or MDRO risk)

---

## 4. SURGICAL SITE INFECTION (SSI)

### **Classification:**

| **Type** | **Timing** | **Involvement** |
|----------|------------|-----------------|
| **Superficial Incisional** | **≤30 days** post-op | Skin/subcutaneous tissue |
| **Deep Incisional** | **≤30 days** (OR ≤90 days if implant) | Deep soft tissue (fascia, muscle) |
| **Organ/Space** | **≤30 days** (OR ≤90 days if implant) | Any organ/space opened during surgery |

---

### **Common Pathogens by Surgery Type:**

| **Surgery Type** | **Common Pathogens** |
|------------------|----------------------|
| **Clean (cardiac, orthopedic)** | **S. aureus (MRSA, MSSA), CoNS** |
| **Clean-contaminated (GI, GYN)** | **Enterobacteriaceae, Enterococcus, anaerobes** (B. fragilis) |
| **Contaminated/dirty** | **Polymicrobial** (Gram-negatives + anaerobes) |

**Key Point:** **Orthopedic/cardiac SSI = S. aureus** (MRSA vs MSSA)

---

### **Management:**

**Step 1: Source Control**
- **Incision and drainage** (if purulent collection)
- **Debridement** (if deep tissue involvement)
- **Remove implant** (if prosthetic joint/device infection refractory to treatment)

**Step 2: Empiric Antibiotics**

| **SSI Type** | **Empiric Regimen** |
|--------------|---------------------|
| **Superficial (clean surgery)** | **Cefazolin** 1-2g IV q8h (covers MSSA)<br>**Add vancomycin** if MRSA risk |
| **Deep incisional/organ-space (GI/GYN)** | **Piperacillin-tazobactam** 4.5g IV q6h OR **ertapenem** 1g IV daily |
| **Necrotizing fasciitis** | **Piperacillin-tazobactam** 4.5g IV q6h + **vancomycin** + **clindamycin** 900 mg IV q8h |

**Step 3: Duration**
- **Superficial:** **5-7 days** (after I&D)
- **Deep/organ-space:** **7-14 days** (individualized)

---

## 5. C. DIFFICILE INFECTION (CDI)

**See dedicated C. diff card for full details**

**Key HAI Considerations:**
- **#1 cause of antibiotic-associated diarrhea** in hospitals
- **Contact precautions + soap and water** (alcohol ineffective)
- **Environmental cleaning with bleach** (1:10 dilution)

---

## SUMMARY TABLE: HAI PREVENTION BUNDLES

| **HAI** | **Key Prevention Strategies** |
|---------|-------------------------------|
| **CLABSI** | Maximal sterile barriers + chlorhexidine skin prep + optimal site selection + daily line necessity review |
| **CAUTI** | Limit catheter use + aseptic insertion + maintain closed drainage + remove ASAP |
| **VAP** | HOB 30-45° + oral chlorhexidine + daily sedation vacation + early extubation |
| **SSI** | Preoperative antibiotics (within 1 hour) + chlorhexidine-alcohol skin prep + clippers (not razors) + normothermia |
| **CDI** | Antimicrobial stewardship + contact precautions + environmental cleaning (bleach) |

---

**Clinical Pearls:**
- **CLABSI: S. aureus or Candida = REMOVE line** (14 days for Candida, 14 days-6 weeks for S. aureus)
- **CAUTI: Do NOT treat asymptomatic bacteriuria** (except pregnancy, urologic surgery)
- **VAP: Late-onset (≥5 days) = MDRO risk** (double Gram-negative + MRSA coverage)
- **SSI: Orthopedic/cardiac = S. aureus** (MRSA vs MSSA)
- **Differential time to positivity (DTP) ≥2 hours** from CVC = suggests CLABSI
- **Prevention bundles = evidence-based interventions** (most HAIs preventable)

**Media:** None

**Sources:** [CDC/NHSN 2024 - HAI surveillance definitions], [IDSA 2024 - HAI management]
